0
0
If you’ve ever been close to addiction — your own or someone else’s — you already know the thing that makes it hard to explain to people who haven’t been there. The problem isn’t the substance. The problem is what keeps calling.
Not an audible voice. More like a signal. Patient, insistent, showing up at the wrong moment with the same offer it always makes. It doesn’t need to argue. It doesn’t need to be persuasive. It just makes itself available and waits for the moment when you’re tired enough, or lonely enough, or numb enough, that the distance between wanting and doing collapses.
Recovery workers have heard thousands of versions of this description. The specifics vary — the substance, the circumstances, the timeline. The underlying architecture is almost always the same: something keeps transmitting. And the central question that addiction medicine has wrestled with for decades is how to quiet the transmission.
A landmark new study suggests that Ozempic — and the class of drugs it belongs to — may actually be able to do exactly that.
The lead researcher described the mechanism in language that is, once you’ve heard it, hard to forget: these drugs quiet the drug noise.
The Study That Changed the Conversation
In June 2026, a landmark paper published in The BMJ drew on one of the largest real-world addiction datasets ever assembled: records from 606,434 U.S. veterans, tracked over time to see what happened when they were prescribed GLP-1 receptor agonists — the drug class that includes Ozempic (semaglutide) and Wegovy — compared to those who weren’t.
The lead researcher was Ziyad Al-Aly, a physician-scientist and clinical epidemiologist at Washington University School of Medicine in St. Louis. His team’s findings, featured in ScienceDaily shortly after publication, were striking in both their scale and their scope.
People taking GLP-1 drugs were 14 percent less likely to develop any substance use disorder at all. For opioids specifically, the risk reduction reached 25 percent. Among people already struggling with addiction, the effects were more dramatic: 40 percent fewer overdoses and 50 percent fewer drug-related deaths.
These weren’t effects confined to one type of substance. They held across alcohol, cannabis, opioids, stimulants — substances with entirely different chemical properties and different mechanisms of action in the brain. Whatever the GLP-1 drugs were affecting, it wasn’t specific to one chemical pathway. It was something more general. Something shared across all forms of compulsive, addictive pursuit.
Al-Aly described the mechanism as quieting “drug noise — the relentless craving that drives addiction across substances.”
That phrase is worth sitting with, because it describes something that anyone who has been near addiction will recognize immediately.
What GLP-1 Drugs Actually Do to the Brain
GLP-1 receptor agonists were developed as metabolic medications. They mimic a naturally occurring gut hormone — glucagon-like peptide 1 — that your body releases after eating. That hormone sends a signal to the brain: you’ve had enough. The appetite quiets. That’s the mechanism behind their effectiveness for weight loss and blood sugar management.
What researchers discovered, largely by observing what happened in people taking these drugs for metabolic reasons, is that the same GLP-1 receptors exist in brain regions associated with reward-seeking behavior — specifically in structures involved in the mesolimbic dopamine pathway. That pathway is not specifically about food. It’s about any reward the brain has learned to pursue: substances, gambling, compulsive behaviors of various kinds.
The working hypothesis is that GLP-1 drugs dampen the craving signal in those regions. They don’t eliminate wanting. They turn down the volume. The transmission that was running at an intensity that overwhelmed deliberate choice becomes quieter — which means the prefrontal cortex, the part of the brain responsible for weighing consequences and making intentional decisions, has more room to actually operate.
This reframes craving as something important: not a moral failing, not a simple choice, not a failure of character or willpower, but a signal. One the brain generates somewhat automatically, somewhat regardless of what the conscious self has decided. A transmission that runs on its own schedule.
That reframing matters enormously for the people who have carried the weight of addiction — and who have often been told, implicitly or explicitly, that continuing to use was a choice they were freely making.
The Architecture of Craving
The neuroscientist Kent Berridge spent decades making a distinction that clarifies the interior experience of addiction: the difference between liking and wanting.
Liking is the actual hedonic pleasure of experiencing something. Wanting is the drive to pursue it. They’re related, but they operate on different circuits — and they can come apart. In addiction, they often do. The person using may have stopped enjoying the substance in any straightforward way. The pleasure diminished long ago. But the wanting intensified, running semi-independently of what the person consciously prefers or has decided.
This is why addiction looks so strange from the outside, and feels so strange from the inside. The person can know, clearly and genuinely, that the substance is destroying their health, their relationships, their finances, their life. They can want to stop. They can intend to stop. The wanting circuit doesn’t update its settings based on that intention. It keeps transmitting — and when the signal runs loud enough, it drowns everything else out.
This is what “drug noise” describes with real precision. Not the pleasure of the substance. The signal. The persistent, unwelcome transmission that occupies attention regardless of what the person has decided. The way a noise can fill a room even when you’d strongly prefer silence.
Quieting that noise, even partially, creates space. The cortex gets room to operate. The deliberate self — the part that has made a clear decision — has a quieter background to work against. The interventions that require volition become more possible when the signal isn’t constantly overwhelming the mind.
This is, apparently, what is happening for hundreds of thousands of people in the Al-Aly study: real reductions in addiction risk, real reductions in overdose and death, traceable to this quieting of the transmission that drives compulsive pursuit.
The findings are significant. The mechanism is real. The drug addresses the signal.
What the Signal Was Covering
But there’s a question the drug leaves open. And it’s one that recovery workers have been sitting with for a long time.
When the noise quiets — what does the person find underneath it?
What were they moving toward, in the moments when the craving called? What were they trying to reach, or escape, or mute, that the substance had been providing a path through? What does the person actually want — not the thing the circuit was generating automatically, but the want underneath the circuit?
The noise and the want aren’t the same thing. The noise is the signal. The want is what the signal was pointing at — and in many cases, covering. People who’ve been through recovery often describe something like this: when the substance goes away, for the first time in years, they have to actually meet themselves. What they find there isn’t always simple. Sometimes it’s grief that predates the substance by decades. Sometimes it’s a persistent sense of wrongness in one’s life that was being muffled. Sometimes it’s the disorienting experience of learning who you are when the circuit isn’t running the agenda.
Quieting the signal doesn’t resolve what the signal was covering. It makes the underlying want audible. And an audible want has to go somewhere.
This is where the Ozempic findings are genuinely significant — and genuinely limited at the same time. Reducing the amplitude of the craving creates space for deliberate choice. That’s real, and it saves lives. But the choice still has to be made. And the question of what the person is choosing toward — what they actually want when the noise isn’t drowning out everything else — is a question the drug cannot answer for them.
Someone Described This 2,000 Years Ago
Here’s the part of this story that doesn’t appear in the BMJ.
Around 2,000 years ago, a man named Paul wrote a letter from a Roman prison cell. He wasn’t writing about addiction — the pharmacological concept didn’t exist yet. He was writing about the human will under a particular kind of siege: the experience of doing the thing you have clearly decided not to do. The gap between intention and action that doesn’t close through effort alone.
His description is not abstract or theoretical. It’s confessional. First person. Present tense:
I do not understand what I do. For what I want to do I do not do, but what I hate I do.
Then, a few lines later, from the opposite direction:
I have the desire to do what is good, but I cannot carry it out.
He wasn’t writing about substances. But anyone who has lived with compulsive behavior — or watched someone they loved live with it — will recognize the architecture immediately. Not description observed from the outside. Testimony from inside. The wanting and the doing, disconnected. The intention and the action, pulling in opposite directions. The thing you hate, happening again.
This is what the mesolimbic dopamine pathway does to a person. Paul didn’t have that language. What he had was something older: close, sustained observation of his own interior life, compressed into the kind of precision that survives two thousand years of translation because it’s describing something real that doesn’t change.
His description maps directly to what neuroscience is now calling the craving circuit. But what he was writing about wasn’t only the signal. He was writing about the divided self underneath the signal. The will that knows one thing and keeps arriving somewhere else. Not the noise the drug can quiet. What lies beneath the noise.
His letter doesn’t stop at the diagnosis. It moves toward something he found — not a suppression of the craving but a different kind of freedom. And he ended the same passage with a question that reads, 2,000 years later, like the exact question every person in recovery eventually has to ask:
Who will rescue me?
Not: how do I quiet the signal? But: who will address the want underneath it?
The answer he arrived at was that something had already acted on the problem at the level of condemnation itself — releasing the person not just from the noise but from the cycle of shame that feeds the noise. The craving circuit runs partly on failure: the shame of relapse, the accumulated weight of the gap between who you want to be and what you keep doing. Paul described something that addressed that weight directly — not demanding the person fix themselves before being accepted, but meeting them in the middle of the divided will and working from there.
The drug quiets what the brain generates automatically. What Paul was describing was the transformation of what a person is genuinely oriented toward — from the inside out. Not signal suppression. The renovation of the want itself.
What Both Findings Point To
These two observations — the 2026 BMJ study and Paul’s letter from a Roman prison — aren’t in competition. They’re addressing different layers of the same territory.
The GLP-1 findings are real. Reducing the amplitude of the craving signal creates space for deliberate choice. For 606,434 veterans, that reduction translated into fewer addictions developed, fewer overdoses, fewer deaths. That is not a small thing. That is everything to the people it reached — and to the people who love them.
But craving doesn’t exist in isolation from what the person actually wants. The circuit runs loud, but the underlying want — for relief, for connection, for something that would fill what’s empty or mute what’s loud — was there first. When the circuit quiets, that want surfaces. It doesn’t disappear. It has to go somewhere.
The oldest literature on human transformation kept arriving at a consistent observation: addressing the surface signal leaves the interior question untouched. What changes a person at the level of what they’re genuinely oriented toward is different in kind from signal suppression. It’s slower. It’s more interior. And it’s the territory that every person who has stayed in recovery long enough eventually has to navigate.
If you’re in that territory — or if someone you love is — the question underneath the noise isn’t empty. And people have been finding their way through it, with help, for a very long time.
If you want to go deeper into that interior work — into who you are underneath the noise and what you’re actually reaching for — 30 Days Walking with Jesus is a day-by-day journey through the words and life of the person Paul’s letter was ultimately pointing toward: what he taught about transformation, about the divided will, about what genuine change looks like from the inside. Not a program. A companion for the kind of interior work that begins when the noise gets quiet enough to hear the question.
This piece is part of an ongoing look at what neuroscience and ancient wisdom are mapping together. The anxiety circuit article explores what a 2026 iScience study found about the specific neurons that switch anxiety on and off — and what Solomon described 3,000 years before the lab. Why Gratitude Changes the Brain covers what happens neurologically when people practice thanksgiving — and what the Psalms were prescribing centuries before the first fMRI.
The drug is new. The observation underneath it is very old. Both are pointing at the same interior terrain.
